Definium says LSD-based DT120 eases generalized anxiety in late-stage trial
Definium Therapeutics said its LSD-based DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study.
Definium Therapeutics NASDAQ:DFTX said its LSD-based treatment reduced symptoms of generalized anxiety disorder in a second successful late-stage study, with shares rising nearly 20% in premarket trading on Monday. A single 100-microgram dose of DT120, a fast-d…